Cell cycle inhibitors - CDK4/6 inhibitors

This video discusses the mechanism of action of cancer therapies - cell cycle inhibitors - CDK4/6 inhibitors. #science #cancer #medicine More videos coming soon. Please rate☝️, comment👇, and subscribe☝️ if you like them, so that I can make more! Please send through requests for topics to cover as well. What do you want to learn about? #scienceinmotion Social Check out other socials: TikTok - @scienceinmotion Instagram - Twitter - Facebook - Website - Music & images Music thanks to: Vyond Some images thanks to: Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License. Some images designed by Freepik/vectorpouch/ . Available from: Some images adapted from BioRender. Created with . Available from: Some images designed by Pixabay, licensed under Creative Commons Attribution 3.0 Unported License. Available from: Some images purchased from Shutterstock. Available from: Some footage/images purchased from Storyblocks. Available from: References Howell A. Fulvestrant. In: Schwab M, editor. Encyclopedia of Cancer. Berlin, Heidelberg: Springer Berlin Heidelberg; 2009. p. 1168-71. Imamura Y, Sadar M. Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic2016. Suzuki H, Ueda T, Ichikawa T, Ito H. Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer. 2003;10(2):209-16. Yamaoka M, Hara T, Kusaka M. Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer. Clinical Cancer Research. 2010;16(17):4319. Drudge-Coates L. GnRH blockers: A changing paradigm in the management of prostate cancer2010. 85-92 Ma CX, Reinert T, Chmielewska I, Ellis MJ. Mechanisms of aromatase inhibitor resistance. Nature Reviews Cancer. 2015;15:26 Brodie A, Sabnis G. Adaptive Changes Result in Activation of Alternate Signaling Pathways and Acquisition of Resistance to Aromatase Inhibitors. Clinical Cancer Research. 2011;17(13):4208.1. Pietras RJ, Márquez-Garbán DC. Membrane-Associated Estrogen Receptor Signaling Pathways in Human Cancers. Clinical Cancer Research. 2007;13(16):4672. Makridakis N, Buchanan G, Tilley W, Reichardt J. Androgen metabolic genes in prostate cancer predisposition and progression2005. 2892-903 p. Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors. Clinical Cancer Research. 2017;23(13):3251. Xu H, Yu S, Liu Q, Yuan X, Mani S, Pestell RG, et al. Recent advances of highly selective CDK4/6 inhibitors in breast cancer. Journal of Hematology & Oncology. 2017;10(1):97. Ciruelos E, Pascual T, Arroyo Vozmediano ML, Blanco M, Manso L, Parrilla L, et al. The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer. The Breast. 2014;23(3):201-8. Nathan MR, Schmid P. A Review of Fulvestrant in Breast Cancer. Oncology and Therapy. 2017;5(1):17-29. cancer,oncology,mechanism of action,signalling,signaling,therapy,therapeutic,cell,breast cancer,estrogen,oestrogen,selective estrogen receptor modulator,receptor,DNA,nucleus,cell cycle